Redcare Pharmacy’s Frankfurt Cheer Fails to Lift Shares Ahead of Half-Year Report

Upbeat conference fails to halt Redcare share slide; market awaits July 29 half-year results as margin contraction and competition weigh.

The upbeat tone struck by Redcare Pharmacy’s management at the Deutsche Bank dbAccess European Champions Conference in Frankfurt has so far failed to stop the bleeding in the stock. While executives voiced confidence in the current year and described the second quarter as tracking well, investors remained unconvinced—the shares shed around three percent on the day following the event. The market is now eyeing hard data rather than warm words, with the half-year report scheduled for 29 July 2026 set to be the real test.

Deutsche Bank analysts, who maintained their positive rating on the stock after the conference, noted that the management gave no indication of walking back its full-year targets. Those targets, laid out alongside the first-quarter numbers in early May, call for revenue growth of 13 to 15 percent in 2026. The German prescription drug segment alone is expected to surpass €670 million, while the adjusted EBITDA margin is projected to hit at least 2.5 percent. The first quarter provided a foundation: adjusted EBITDA rose to €14.4 million from €9.1 million a year earlier, lifting the margin to 1.7 percent—still a long way from the full-year goal.

The margin story, however, remains the central worry. The gross margin contracted to 21.0 percent in the first quarter, down from 23.3 percent a year ago. Redcare attributes the squeeze to fiercer competition in the over-the-counter segment, a rising share of structurally lower-margin prescription business, and a prescription bonus introduced in mid-September 2025. On the cost side, there is progress: adjusted selling and distribution expenses fell to 16.8 percent of revenue, compared with 19.4 percent in the prior-year period, thanks to more efficient marketing and fixed-cost leverage. But these improvements have only partly offset the gross margin compression.

The share price tells a more brutal story. At its latest close of €43.14, the stock stands roughly 63 percent below its 52-week high of €117.40 struck in May 2025. Year-to-date, the equity has shed more than a third of its value. Technically, the shares are hovering near their 50-day moving average, but the 200-day average of €61.08—almost 30 percent above the current price—remains a distant target. The relative strength index sits at about 50, indicating neither oversold nor overbought conditions, leaving the stock in technical limbo.

Broader sector headwinds are adding to the pressure. European pharmacy markets are grappling with severe medicine shortages; in May alone, 219 different products were unavailable in the United Kingdom, including heart medications such as Ramipril and Bisoprolol, antibiotics and antidepressants. Community Pharmacy England warned of serious consequences for patient care, and geopolitical strains are exacerbating supply-chain disruptions. For an online pharmacy platform like Redcare, which depends on reliable logistics, this is no abstract worry.

Longer-term, structural arguments for the sector remain intact. The pharmaceutical industry invests roughly 20 percent of revenue in research and development, and a recent Ifo study pegs its annual contribution to German value creation at around €55 billion. New growth avenues, such as the professionalised medical cannabis distribution network emerging in Germany, could also benefit digital pharmacy players. None of this, however, changes the immediate picture: Redcare shares are trapped between the 50-day moving average and a 52-week low of €31.00, with the 200-day average far above.

The half-year report on 29 July will either validate management’s upbeat tone from Frankfurt or expose the gap between confidence and reality. The trajectory of prescription-drug growth, the intensity of non-prescription competition and—above all—the path of the adjusted EBITDA margin will determine whether the 2.5 percent full-year target remains plausible. For now, investors are waiting for numbers, not promises.